Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan, China.
Department of Respiratory and Critical Care Medicine, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
BMC Pulm Med. 2023 Nov 24;23(1):470. doi: 10.1186/s12890-023-02772-2.
The activated complement cascade is involved in asthmatic airway inflammation. Ficolins are essential for innate immunity and can activate the complement lectin pathway. Despite this, the significance of ficolins in asthma has yet to be determined. This study aimed to explore the presence of ficolins in individuals with asthma and to determine the relationship between ficolins and clinical characteristics.
For the study, 68 asthmatic patients and 30 healthy control subjects were recruited. Enzyme-linked immunosorbent assay was used to determine plasma ficolin-1, ficolin-2, and ficolin-3 concentrations both before and after inhaled corticosteroid (ICS) therapy. Further, the associations of plasma ficolin-1 level with pulmonary function and asthma control questionnaire (ACQ) score were examined in the asthma patients.
Patients with asthma exhibited significantly elevated plasma ficolin-1 levels (median, 493.9 ng/mL; IQR, 330.2-717.8 ng/mL) in comparison to healthy controls (median, 330.6 ng/mL; IQR, 233.8-371.1 ng/mL). After ICS treatment, plasma ficolin-1 (median, 518.1 ng/mL; IQR, 330.2-727.0 ng/mL) in asthmatic patients was significantly reduced (median, 374.7 ng/mL; IQR, 254.8-562.5 ng/mL). Additionally, ficolin-1 expressions in plasma were significantly correlated with pulmonary function parameters and ACQ score in asthmatic patients. Asthma patients with higher plasma ficolin-1 levels demonstrated poorer lung function than those with lower plasma ficolin-1 levels.
The results revealed that asthmatic patients had higher plasma ficolin-1 concentrations, which decreased after ICS treatment and were linked to their lung function, implying a potential involvement of ficolin-1 in asthma pathogenesis.
激活的补体级联反应参与了哮喘气道炎症。纤维胶凝蛋白对于先天免疫至关重要，并且可以激活补体凝集素途径。尽管如此，纤维胶凝蛋白在哮喘中的意义尚未确定。本研究旨在探讨哮喘患者中纤维胶凝蛋白的存在，并确定纤维胶凝蛋白与临床特征之间的关系。
研究纳入了 68 例哮喘患者和 30 名健康对照者。使用酶联免疫吸附试验（ELISA）测定皮质类固醇吸入治疗前后患者和健康对照者的血浆纤维胶凝蛋白-1、纤维胶凝蛋白-2 和纤维胶凝蛋白-3 浓度。此外，还检测了哮喘患者血浆纤维胶凝蛋白-1 水平与肺功能和哮喘控制问卷（ACQ）评分之间的相关性。
与健康对照组相比，哮喘患者的血浆纤维胶凝蛋白-1 水平明显升高（中位数 493.9ng/mL；IQR 330.2-717.8ng/mL）。皮质类固醇吸入治疗后，哮喘患者的血浆纤维胶凝蛋白-1 水平（中位数 518.1ng/mL；IQR 330.2-727.0ng/mL）显著降低（中位数 374.7ng/mL；IQR 254.8-562.5ng/mL）。此外，哮喘患者的血浆纤维胶凝蛋白-1 表达与肺功能参数和 ACQ 评分显著相关。血浆纤维胶凝蛋白-1 水平较高的哮喘患者的肺功能较血浆纤维胶凝蛋白-1 水平较低的患者差。
结果表明，哮喘患者的血浆纤维胶凝蛋白-1 浓度较高，皮质类固醇吸入治疗后降低，且与肺功能相关，提示纤维胶凝蛋白-1 可能参与哮喘的发病机制。
